Harrow, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award
Harrow, Inc. (HROW) reported Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award of 15.00 thousand shares for the 9-month period ending 2016-09-30, per its 10-Q filed 2016-11-14.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward · last filed 2016-11-14
- Harrow, Inc. share-based compensation arrangement by share-based payment award, shares purchased for award for the quarter ending 2016-09-30 was 0.00 shares.
- Harrow, Inc. share-based compensation arrangement by share-based payment award, shares purchased for award for the quarter ending 2016-06-30 was 0.00 shares.
- Harrow, Inc. share-based compensation arrangement by share-based payment award, shares purchased for award for the quarter ending 2016-03-31 was 15.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award 9 month |
|---|---|---|---|
| 2016-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | 0.00 shares derived: sum of 2 quarters · filed 2016-11-14 | 15.00K shares 10-Q · filed 2016-11-14 |
| 2016-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | 15.00K shares 10-Q · filed 2016-08-15 | |
| 2016-03-31 | 15.00K shares 10-Q · filed 2016-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |